Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Nuveen Asset Management LLC Grows Position in Fate Therapeutics Inc (NASDAQ:FATE)
07:04am, Wednesday, 24'th Jun 2020
Nuveen Asset Management LLC grew its position in Fate Therapeutics Inc (NASDAQ:FATE) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Ex
Notable Insider Buys Last Week: Cigna, Fox, Uber And More
12:00am, Saturday, 20'th Jun 2020
Insider buying can be an encouraging signal for potential investors.
Some insiders took advantage of a secondary offering last week.
Two chief executives also have stepped up to...
AlphaCrest Capital Management LLC Purchases New Position in Fate Therapeutics Inc (NASDAQ:FATE)
07:20am, Tuesday, 16'th Jun 2020
AlphaCrest Capital Management LLC purchased a new stake in Fate Therapeutics Inc (NASDAQ:FATE) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchas
Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)
05:44pm, Monday, 15'th Jun 2020
In this article we will check out the progression of hedge fund sentiment towards Fate Therapeutics Inc (NASDAQ:FATE) and determine whether it is a good investment right now. We at Insider Monkey like
If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now
11:50am, Saturday, 13'th Jun 2020
Here's how much you'd have if you'd invested in this mid-cap biotech company that's developing the next generation of cancer immunotherapies.
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cance
Global CAR-T Therapy Market Assessment 2020-2030 - ResearchAndMarkets.com
12:00am, Thursday, 11'th Jun 2020
The
Fate Therapeutics (NASDAQ:FATE) Coverage Initiated at Oppenheimer
03:38am, Wednesday, 10'th Jun 2020
Analysts at Oppenheimer assumed coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research report issued on Tuesday, TipRanks reports. The firm set a “buy” rating and a $40.00 price targe
Here's Why Fate Therapeutics Rose 18.4% in May
09:29pm, Tuesday, 09'th Jun 2020
On May 20, the development-stage company announced the U.S. Food and Drug Administration (FDA) cleared a new drug candidate to begin clinical trials. Identified as FT538, the drug candidate is the fi
Here's Why Fate Therapeutics Stock Jumped Higher Today
06:10pm, Tuesday, 09'th Jun 2020
Shares of Fate Therapeutics (NASDAQ: FATE) were up 19% to $33.73 at 1:39 p.m. EDT on Tuesday after the company raised at least $214 million through a public secondary offering and a private placement
Fate Therapeutics Announces Pricing of Public Offering of Common Stock
04:49am, Tuesday, 09'th Jun 2020
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 8)
Biohaven Pharmaceutical...
Fate Therapeutics Announces Proposed Public Offering of Common Stock; No Terms Disclosed
08:02pm, Monday, 08'th Jun 2020Fate Therapeutics Announces Proposed Public Offering of Common Stock
08:01pm, Monday, 08'th Jun 2020
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer
